Praxis Precision Medicines (Praxis Precision Medicines) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines Change In Receivables?

Praxis Precision Medicines's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Praxis Precision Medicines's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Praxis Precision Medicines's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Praxis Precision Medicines's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Praxis Precision Medicines's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Praxis Precision Medicines's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Praxis Precision Medicines's liquidation value for the three months ended in Dec. 2023 was $63.02 Mil.

Praxis Precision Medicines Change In Receivables Historical Data

The historical data trend for Praxis Precision Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines Change In Receivables Chart

Praxis Precision Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Praxis Precision Medicines Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Praxis Precision Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Praxis Precision Medicines (NAS:PRAX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Praxis Precision Medicines's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.515	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Praxis Precision Medicines's accounts receivable are only considered to be worth 75% of book value:

Praxis Precision Medicines's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	81.3	-	18.279	+	0.75 * 0	+	0.5 * 0
=	63.02

Praxis Precision Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Praxis Precision Medicines (Praxis Precision Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 High Street, 30th Floor, Boston, MA, USA, 02110

Website

https://www.praxismedicines.com

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Executives

Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza	officer: Chief Executive Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly	officer: Chief Financial Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola	officer: Principal Accounting Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Alex Nemiroff	officer: General Counsel and Secretary	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154